DUBLIN–(BUSINESS WIRE)–The “Transdermal Drug Delivery System Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type; Application; End User; and Geography” report has been added to ResearchAndMarkets.com’s offering.

The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027.

The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Transdermal drug delivery systems are devices containing drug of defined surface area that delivers a pre-determined amount of drug to the surface of intact skin at a pre-predefined rate. The skin as a route for systemic drug administration has become very attractive since the introduction of transdermal therapeutic systems in the form of patches. The discovery of transdermal drug delivery systems (TDDS) is breakthrough in the field of controlled drug delivery system. Transdermal dosage forms, as an alternative to the conventional dosage form are becoming very popular because of their unique advantages. Like controlled zero ordered absorption, simple mode of administration and having option to terminate the action in case of adverse effect. So the TDDS makes them desirable for the treatment of chronic diseases where long term treatment is necessary. According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Cardiovascular (CV) diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are the major cause of mortality in the whole world owing to the present day hectic lifestyle. (Read more…) As per the data provided by WHO, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Many medications are commercially available for their treatment but the conventional tablets and capsules are unable to cope up with these situations.

This augments the use of novel drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Novel drug delivery systems started with the platform application involving the introduction of transdermal patches, containing drug particles, were applied on skin. They are believed to offer many advantages over conventional oral therapies. Moreover, sizeable number of anti-hypertensive is undergoing extensive first-pass metabolism, which can be avoided by transdermal therapy. Hence, the adoption of transdermal drug delivery systems is likely to experience rapid adoption, which in turn is propelling the market growth.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the transdermal drug delivery system market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global transdermal drug delivery system market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases
• Growing Demand for Non-Invasive Drug Delivery Devices
• High Demand for Self-Administration of Drugs

Restraints

• High Cost Involved in Development of Drug Delivery Systems
• Drug Failure and Recalls of Transdermal Drug Delivery Systems

Opportunities

• Strategic Activities by the Manufacturers

Future Trends

• Rise in Adoption of Third-Generation Delivery Systems

Companies Mentioned

• Novartis Ag
• Johnson & Johnson Services, Inc.
• Glaxosmithkline Plc.
• Bayer Ag
• Mylan N.V.
• Boehringer Ingelheim International Gmbh
• Hisamitsu Pharmaceutical Co.,Inc.
• Luye Pharma Group
• Purdue Pharma LP.
• Lavipharm

For more information about this report visit https://www.researchandmarkets.com/r/is8cix

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Transdermal Drug Delivery System Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type; Application; End User; and Geography” report has been added to ResearchAndMarkets.com’s offering.

The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027.

The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Transdermal drug delivery systems are devices containing drug of defined surface area that delivers a pre-determined amount of drug to the surface of intact skin at a pre-predefined rate. The skin as a route for systemic drug administration has become very attractive since the introduction of transdermal therapeutic systems in the form of patches. The discovery of transdermal drug delivery systems (TDDS) is breakthrough in the field of controlled drug delivery system. Transdermal dosage forms, as an alternative to the conventional dosage form are becoming very popular because of their unique advantages. Like controlled zero ordered absorption, simple mode of administration and having option to terminate the action in case of adverse effect. So the TDDS makes them desirable for the treatment of chronic diseases where long term treatment is necessary. According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Cardiovascular (CV) diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are the major cause of mortality in the whole world owing to the present day hectic lifestyle. (Read more…) As per the data provided by WHO, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Many medications are commercially available for their treatment but the conventional tablets and capsules are unable to cope up with these situations.

This augments the use of novel drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Novel drug delivery systems started with the platform application involving the introduction of transdermal patches, containing drug particles, were applied on skin. They are believed to offer many advantages over conventional oral therapies. Moreover, sizeable number of anti-hypertensive is undergoing extensive first-pass metabolism, which can be avoided by transdermal therapy. Hence, the adoption of transdermal drug delivery systems is likely to experience rapid adoption, which in turn is propelling the market growth.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the transdermal drug delivery system market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global transdermal drug delivery system market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases
• Growing Demand for Non-Invasive Drug Delivery Devices
• High Demand for Self-Administration of Drugs

Restraints

• High Cost Involved in Development of Drug Delivery Systems
• Drug Failure and Recalls of Transdermal Drug Delivery Systems

Opportunities

• Strategic Activities by the Manufacturers

Future Trends

• Rise in Adoption of Third-Generation Delivery Systems

Companies Mentioned

• Novartis Ag
• Johnson & Johnson Services, Inc.
• Glaxosmithkline Plc.
• Bayer Ag
• Mylan N.V.
• Boehringer Ingelheim International Gmbh
• Hisamitsu Pharmaceutical Co.,Inc.
• Luye Pharma Group
• Purdue Pharma LP.
• Lavipharm

For more information about this report visit https://www.researchandmarkets.com/r/is8cix

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Transdermal Drug Delivery System Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type; Application; End User; and Geography” report has been added to ResearchAndMarkets.com’s offering.

The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027.

The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Transdermal drug delivery systems are devices containing drug of defined surface area that delivers a pre-determined amount of drug to the surface of intact skin at a pre-predefined rate. The skin as a route for systemic drug administration has become very attractive since the introduction of transdermal therapeutic systems in the form of patches. The discovery of transdermal drug delivery systems (TDDS) is breakthrough in the field of controlled drug delivery system. Transdermal dosage forms, as an alternative to the conventional dosage form are becoming very popular because of their unique advantages. Like controlled zero ordered absorption, simple mode of administration and having option to terminate the action in case of adverse effect. So the TDDS makes them desirable for the treatment of chronic diseases where long term treatment is necessary. According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Cardiovascular (CV) diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are the major cause of mortality in the whole world owing to the present day hectic lifestyle. (Read more…) As per the data provided by WHO, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Many medications are commercially available for their treatment but the conventional tablets and capsules are unable to cope up with these situations.

This augments the use of novel drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Novel drug delivery systems started with the platform application involving the introduction of transdermal patches, containing drug particles, were applied on skin. They are believed to offer many advantages over conventional oral therapies. Moreover, sizeable number of anti-hypertensive is undergoing extensive first-pass metabolism, which can be avoided by transdermal therapy. Hence, the adoption of transdermal drug delivery systems is likely to experience rapid adoption, which in turn is propelling the market growth.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the transdermal drug delivery system market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global transdermal drug delivery system market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases
• Growing Demand for Non-Invasive Drug Delivery Devices
• High Demand for Self-Administration of Drugs

Restraints

• High Cost Involved in Development of Drug Delivery Systems
• Drug Failure and Recalls of Transdermal Drug Delivery Systems

Opportunities

• Strategic Activities by the Manufacturers

Future Trends

• Rise in Adoption of Third-Generation Delivery Systems

Companies Mentioned

• Novartis Ag
• Johnson & Johnson Services, Inc.
• Glaxosmithkline Plc.
• Bayer Ag
• Mylan N.V.
• Boehringer Ingelheim International Gmbh
• Hisamitsu Pharmaceutical Co.,Inc.
• Luye Pharma Group
• Purdue Pharma LP.
• Lavipharm

For more information about this report visit https://www.researchandmarkets.com/r/is8cix

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Transdermal Drug Delivery System Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type; Application; End User; and Geography” report has been added to ResearchAndMarkets.com’s offering.

The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027.

The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Transdermal drug delivery systems are devices containing drug of defined surface area that delivers a pre-determined amount of drug to the surface of intact skin at a pre-predefined rate. The skin as a route for systemic drug administration has become very attractive since the introduction of transdermal therapeutic systems in the form of patches. The discovery of transdermal drug delivery systems (TDDS) is breakthrough in the field of controlled drug delivery system. Transdermal dosage forms, as an alternative to the conventional dosage form are becoming very popular because of their unique advantages. Like controlled zero ordered absorption, simple mode of administration and having option to terminate the action in case of adverse effect. So the TDDS makes them desirable for the treatment of chronic diseases where long term treatment is necessary. According to the Centers for Disease Control and Prevention (CDC) in the 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Cardiovascular (CV) diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are the major cause of mortality in the whole world owing to the present day hectic lifestyle. (Read more…) As per the data provided by WHO, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Many medications are commercially available for their treatment but the conventional tablets and capsules are unable to cope up with these situations.

This augments the use of novel drug delivery systems providing targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Novel drug delivery systems started with the platform application involving the introduction of transdermal patches, containing drug particles, were applied on skin. They are believed to offer many advantages over conventional oral therapies. Moreover, sizeable number of anti-hypertensive is undergoing extensive first-pass metabolism, which can be avoided by transdermal therapy. Hence, the adoption of transdermal drug delivery systems is likely to experience rapid adoption, which in turn is propelling the market growth.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the transdermal drug delivery system market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global transdermal drug delivery system market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases
• Growing Demand for Non-Invasive Drug Delivery Devices
• High Demand for Self-Administration of Drugs

Restraints

• High Cost Involved in Development of Drug Delivery Systems
• Drug Failure and Recalls of Transdermal Drug Delivery Systems

Opportunities

• Strategic Activities by the Manufacturers

Future Trends

• Rise in Adoption of Third-Generation Delivery Systems

Companies Mentioned

• Novartis Ag
• Johnson & Johnson Services, Inc.
• Glaxosmithkline Plc.
• Bayer Ag
• Mylan N.V.
• Boehringer Ingelheim International Gmbh
• Hisamitsu Pharmaceutical Co.,Inc.
• Luye Pharma Group
• Purdue Pharma LP.
• Lavipharm

For more information about this report visit https://www.researchandmarkets.com/r/is8cix

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900